MiR-22 as a metabolic silencer and liver tumor suppressor

With obesity rate consistently increasing, a strong relationship between obesity and fatty liver disease has been discovered. More than 90% of bariatric surgery patients also have non-alcoholic fatty liver diseases (NAFLDs). NAFLD and non-alcoholic steatohepatitis (NASH), which are the hepatic manif...

Full description

Saved in:
Bibliographic Details
Published in:Liver research 2020-06, Vol.4 (2), p.74-80
Main Authors: Wang, Lijun, Wang, Yu-Shiuan, Mugiyanto, Eko, Chang, Wei-Chiao, Wan, Yu-Jui Yvonne
Format: Article
Language:English
Subjects:
Cancer
Hepatitis
Liver
Metabolism
MicroRNA-22(miR-22)
Non-alcoholic steatohepatitis
Steatosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4211-7f75d701ac2e3b26255b36f996069574d9bc6da2f4b0508e1f1ab0fcca72485f3
cites cdi_FETCH-LOGICAL-c4211-7f75d701ac2e3b26255b36f996069574d9bc6da2f4b0508e1f1ab0fcca72485f3
container_end_page 80
container_issue 2
container_start_page 74
container_title Liver research
container_volume 4
creator Wang, Lijun
Wang, Yu-Shiuan
Mugiyanto, Eko
Chang, Wei-Chiao
Wan, Yu-Jui Yvonne
description With obesity rate consistently increasing, a strong relationship between obesity and fatty liver disease has been discovered. More than 90% of bariatric surgery patients also have non-alcoholic fatty liver diseases (NAFLDs). NAFLD and non-alcoholic steatohepatitis (NASH), which are the hepatic manifestations of metabolic syndrome, can lead to liver carcinogenesis. Unfortunately, there is no effective medicine that can be used to treat NASH or liver cancer. Thus, it is critically important to understand the mechanism underlying the development of these diseases. Extensive evidence suggests that microRNA 22 (miR-22) can be a diagnostic marker for liver diseases as well as a treatment target. This review paper focuses on the roles of miR-22 in metabolism, steatosis, and liver carcinogenesis. Literature search is limited based on the publications included in the PubMed database in the recent 10 years.
doi_str_mv 10.1016/j.livres.2020.06.001
format article
fullrecord <record><control><sourceid>elsevier_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a22acb35eec1404c84017d9a6a326ab0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2542568420300246</els_id><doaj_id>oai_doaj_org_article_a22acb35eec1404c84017d9a6a326ab0</doaj_id><sourcerecordid>S2542568420300246</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4211-7f75d701ac2e3b26255b36f996069574d9bc6da2f4b0508e1f1ab0fcca72485f3</originalsourceid><addsrcrecordid>eNp9kVtLxDAQhYMoKuo_8KF_oHUyubUvgog3UATR5zBNU83S3S5Jd8F_b9YVLy8-zWGSfIecw9gph4oD12ezagjr6FOFgFCBrgD4DjtEJbFUupa7v_QBO0lpBvlGjVoruc8OhABQ0shD1jyEpxKxoFRQMfcTteMQXJHC4BfOx4IWXZGtsppW8zEWabVcZt80xmO219OQ_MnXPGIv11fPl7fl_ePN3eXFfekkcl6a3qjOACeHXrSoUalW6L5pNOhGGdk1rdMdYS9bUFB73nNqoXeODMpa9eKI3W253Ugzu4xhTvHdjhTs52KMr5biFNzgLSGSa4Xy3nEJ0tUSuOka0iRQZ2pmnW9Zy1U7953ziynS8Af692QR3uzruLZGoTAgMkBuAS6OKUXff7_lYDfN2JndNmM3zVjQNuf-4-tzUOvgo00ubALuQvRuyj8J_wM-AIhnlvU</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>MiR-22 as a metabolic silencer and liver tumor suppressor</title><source>ScienceDirect Journals</source><creator>Wang, Lijun ; Wang, Yu-Shiuan ; Mugiyanto, Eko ; Chang, Wei-Chiao ; Wan, Yu-Jui Yvonne</creator><creatorcontrib>Wang, Lijun ; Wang, Yu-Shiuan ; Mugiyanto, Eko ; Chang, Wei-Chiao ; Wan, Yu-Jui Yvonne</creatorcontrib><description>With obesity rate consistently increasing, a strong relationship between obesity and fatty liver disease has been discovered. More than 90% of bariatric surgery patients also have non-alcoholic fatty liver diseases (NAFLDs). NAFLD and non-alcoholic steatohepatitis (NASH), which are the hepatic manifestations of metabolic syndrome, can lead to liver carcinogenesis. Unfortunately, there is no effective medicine that can be used to treat NASH or liver cancer. Thus, it is critically important to understand the mechanism underlying the development of these diseases. Extensive evidence suggests that microRNA 22 (miR-22) can be a diagnostic marker for liver diseases as well as a treatment target. This review paper focuses on the roles of miR-22 in metabolism, steatosis, and liver carcinogenesis. Literature search is limited based on the publications included in the PubMed database in the recent 10 years.</description><identifier>ISSN: 2542-5684</identifier><identifier>ISSN: 2096-2878</identifier><identifier>EISSN: 2542-5684</identifier><identifier>DOI: 10.1016/j.livres.2020.06.001</identifier><identifier>PMID: 33005474</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Cancer ; Hepatitis ; Liver ; Metabolism ; MicroRNA-22(miR-22) ; Non-alcoholic steatohepatitis ; Steatosis</subject><ispartof>Liver research, 2020-06, Vol.4 (2), p.74-80</ispartof><rights>2020 The Third Affiliated Hospital of Sun Yat-sen University</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4211-7f75d701ac2e3b26255b36f996069574d9bc6da2f4b0508e1f1ab0fcca72485f3</citedby><cites>FETCH-LOGICAL-c4211-7f75d701ac2e3b26255b36f996069574d9bc6da2f4b0508e1f1ab0fcca72485f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2542568420300246$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3549,27924,27925,45780</link.rule.ids></links><search><creatorcontrib>Wang, Lijun</creatorcontrib><creatorcontrib>Wang, Yu-Shiuan</creatorcontrib><creatorcontrib>Mugiyanto, Eko</creatorcontrib><creatorcontrib>Chang, Wei-Chiao</creatorcontrib><creatorcontrib>Wan, Yu-Jui Yvonne</creatorcontrib><title>MiR-22 as a metabolic silencer and liver tumor suppressor</title><title>Liver research</title><description>With obesity rate consistently increasing, a strong relationship between obesity and fatty liver disease has been discovered. More than 90% of bariatric surgery patients also have non-alcoholic fatty liver diseases (NAFLDs). NAFLD and non-alcoholic steatohepatitis (NASH), which are the hepatic manifestations of metabolic syndrome, can lead to liver carcinogenesis. Unfortunately, there is no effective medicine that can be used to treat NASH or liver cancer. Thus, it is critically important to understand the mechanism underlying the development of these diseases. Extensive evidence suggests that microRNA 22 (miR-22) can be a diagnostic marker for liver diseases as well as a treatment target. This review paper focuses on the roles of miR-22 in metabolism, steatosis, and liver carcinogenesis. Literature search is limited based on the publications included in the PubMed database in the recent 10 years.</description><subject>Cancer</subject><subject>Hepatitis</subject><subject>Liver</subject><subject>Metabolism</subject><subject>MicroRNA-22(miR-22)</subject><subject>Non-alcoholic steatohepatitis</subject><subject>Steatosis</subject><issn>2542-5684</issn><issn>2096-2878</issn><issn>2542-5684</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kVtLxDAQhYMoKuo_8KF_oHUyubUvgog3UATR5zBNU83S3S5Jd8F_b9YVLy8-zWGSfIecw9gph4oD12ezagjr6FOFgFCBrgD4DjtEJbFUupa7v_QBO0lpBvlGjVoruc8OhABQ0shD1jyEpxKxoFRQMfcTteMQXJHC4BfOx4IWXZGtsppW8zEWabVcZt80xmO219OQ_MnXPGIv11fPl7fl_ePN3eXFfekkcl6a3qjOACeHXrSoUalW6L5pNOhGGdk1rdMdYS9bUFB73nNqoXeODMpa9eKI3W253Ugzu4xhTvHdjhTs52KMr5biFNzgLSGSa4Xy3nEJ0tUSuOka0iRQZ2pmnW9Zy1U7953ziynS8Af692QR3uzruLZGoTAgMkBuAS6OKUXff7_lYDfN2JndNmM3zVjQNuf-4-tzUOvgo00ubALuQvRuyj8J_wM-AIhnlvU</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Wang, Lijun</creator><creator>Wang, Yu-Shiuan</creator><creator>Mugiyanto, Eko</creator><creator>Chang, Wei-Chiao</creator><creator>Wan, Yu-Jui Yvonne</creator><general>Elsevier B.V</general><general>KeAi Communications Co., Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202006</creationdate><title>MiR-22 as a metabolic silencer and liver tumor suppressor</title><author>Wang, Lijun ; Wang, Yu-Shiuan ; Mugiyanto, Eko ; Chang, Wei-Chiao ; Wan, Yu-Jui Yvonne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4211-7f75d701ac2e3b26255b36f996069574d9bc6da2f4b0508e1f1ab0fcca72485f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer</topic><topic>Hepatitis</topic><topic>Liver</topic><topic>Metabolism</topic><topic>MicroRNA-22(miR-22)</topic><topic>Non-alcoholic steatohepatitis</topic><topic>Steatosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Lijun</creatorcontrib><creatorcontrib>Wang, Yu-Shiuan</creatorcontrib><creatorcontrib>Mugiyanto, Eko</creatorcontrib><creatorcontrib>Chang, Wei-Chiao</creatorcontrib><creatorcontrib>Wan, Yu-Jui Yvonne</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Liver research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Lijun</au><au>Wang, Yu-Shiuan</au><au>Mugiyanto, Eko</au><au>Chang, Wei-Chiao</au><au>Wan, Yu-Jui Yvonne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MiR-22 as a metabolic silencer and liver tumor suppressor</atitle><jtitle>Liver research</jtitle><date>2020-06</date><risdate>2020</risdate><volume>4</volume><issue>2</issue><spage>74</spage><epage>80</epage><pages>74-80</pages><issn>2542-5684</issn><issn>2096-2878</issn><eissn>2542-5684</eissn><abstract>With obesity rate consistently increasing, a strong relationship between obesity and fatty liver disease has been discovered. More than 90% of bariatric surgery patients also have non-alcoholic fatty liver diseases (NAFLDs). NAFLD and non-alcoholic steatohepatitis (NASH), which are the hepatic manifestations of metabolic syndrome, can lead to liver carcinogenesis. Unfortunately, there is no effective medicine that can be used to treat NASH or liver cancer. Thus, it is critically important to understand the mechanism underlying the development of these diseases. Extensive evidence suggests that microRNA 22 (miR-22) can be a diagnostic marker for liver diseases as well as a treatment target. This review paper focuses on the roles of miR-22 in metabolism, steatosis, and liver carcinogenesis. Literature search is limited based on the publications included in the PubMed database in the recent 10 years.</abstract><pub>Elsevier B.V</pub><pmid>33005474</pmid><doi>10.1016/j.livres.2020.06.001</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2542-5684
ispartof Liver research, 2020-06, Vol.4 (2), p.74-80
issn 2542-5684
2096-2878
2542-5684
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a22acb35eec1404c84017d9a6a326ab0
source ScienceDirect Journals
subjects Cancer
Hepatitis
Liver
Metabolism
MicroRNA-22(miR-22)
Non-alcoholic steatohepatitis
Steatosis
title MiR-22 as a metabolic silencer and liver tumor suppressor
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T13%3A36%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MiR-22%20as%20a%20metabolic%20silencer%20and%20liver%20tumor%20suppressor&rft.jtitle=Liver%20research&rft.au=Wang,%20Lijun&rft.date=2020-06&rft.volume=4&rft.issue=2&rft.spage=74&rft.epage=80&rft.pages=74-80&rft.issn=2542-5684&rft.eissn=2542-5684&rft_id=info:doi/10.1016/j.livres.2020.06.001&rft_dat=%3Celsevier_doaj_%3ES2542568420300246%3C/elsevier_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4211-7f75d701ac2e3b26255b36f996069574d9bc6da2f4b0508e1f1ab0fcca72485f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/33005474&rfr_iscdi=true